Fireside Panel Discussion on Diabetes sector

About this update from Arecor Therapeutics Plc

  Arecor Therapeutics plc ("Arecor" or the "Company")   Arecor and Sequel Med Tech virtual fireside panel discussion   Cambridge, UK, 6 January 2026 : Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, and Sequel Med Tech LLC ("Sequel"), a company developing state-of-the-art insulin delivery technologies, will be hosting a virtual fireside panel discussion on the future of the treatment journey for people with diabetes and factors driving diabetes innovation, on Wednesday 7 January 2026 at 16:00 GMT / 11:00 ET / 08:00 PT. At this event, no new material information will be disclosed. To register for the event, please email [email protected] or [email protected]. -ENDS- For more information, please contact:   Arecor Therapeutics plc Dr Sarah Howell, Chief Executive Officer David Ellam, Chief Financial Officer +44 (0) 1223 426060 [email protected]     Singer Capital Markets Advisory LLP (NOMAD and Broker to Arecor Therapeutics) +44 (0) 20 7496 3000 Phil Davies, Andrew Johnson, James Todd       Vigo Consulting (IR and PR for Arecor) Melanie Toyne Sewell, Rozi Morris +44 (0) 20 7390 0230 [email protected]     Sequel Med Tech LLC Gabby Fernandes, VP, Finance & Investor Relations   [email protected] Notes to Editors   About Arecor Arecor Therapeutics plc is a clinical stage biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases. The Company is applying its proprietary technology platform, Arestat®, to develop a portfolio of proprietary products, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin. Arecor is also developing a novel oral delivery platform for peptides (e.g. GLP-1 receptor agonists) targeting the obesity and diabetes markets. The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK.  For further details please see www.arecor.com . Arecor® and Arestat® are registered trademarks of Arecor Limited.   About Sequel Med Tech Headquartered in Manchester, New Hampshire, US, Sequel is developing the next generation of transformative drug-delivery advancements. Sequel's approach is to look at diabetes management holistically to advance systems that make living with diabetes simpler and easier for all. Sequel was co-founded by visionary Dean Kamen, serial entrepreneur Pablo Legorreta, seasoned medical device executive Bill Doyle and healthcare leader Alan Lotvin, MD. Sequel's focus is to bring the latest developments in science and technology to the marketplace, helping drive more accessible drug delivery. For more information, please visit  www.sequelmedtech.com .  

View stock analysis, news, and events for Arecor Therapeutics Plc